Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Entire DC Network
Optimization And Toxocologic Effects Of Cancer Immuno-Electrogene Therapy Using A Tumor-Targeted Interleukin-12 Gene Construct, Scott Douglas Reed
Optimization And Toxocologic Effects Of Cancer Immuno-Electrogene Therapy Using A Tumor-Targeted Interleukin-12 Gene Construct, Scott Douglas Reed
LSU Doctoral Dissertations
This dissertation includes a comprehensive current review of reversible electroporation (EP) and other related physical gene transfection techniques; an overview of results of electrochemogene therapy (ECGT) used to treat naturally occurring spontaneous neoplasms in dogs; and the results of comprehensive, pre-clinical toxicology testing of electrogene therapy (EGT) of a tumor-targeted version of interleukin-12 (IL-12) in mice. Intralesional bleomycin (BLM) and feline interleukin-12 (fIL-12) DNA injection combined with trans-lesional EP resulted in complete cure of two recurrent oral squamous cell carcinomas and an acanthomatous ameloblastoma in a series of six cases of spontaneous neoplasia in pet dogs. The three remaining dogs, …
Identification Of A Tumor-Targeting-Peptide And Development Of A Tumor-Targeted-Cytokine Vector For Systemic Treatment Of Primary And Metastatic Malignancies, Jeffry Cutrera
LSU Doctoral Dissertations
Advances in cancer therapies continue to be improved, yet cancer continues to be one of the deadliest diseases in the world. Harnessing the power of the body’s immune system to attack cancer is a promising strategy that can further improve therapies for neoplastic diseases. As part of this strategy, cytokines such as interleukin (IL) 2 and interferon á are currently accepted cancer treatments, and other cytokines such as IL12 and GM-CSF also show potential as new treatments. Clinical trials with these cytokines have shown less than acceptable therapeutic efficacy and toxicities, but tumor-targeting motifs can improve these effects. Both antibodies …